恒瑞医药(01276.HK)：子公司“SHR-9539注射液”及“HRS-3738片”获药物临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-9539 injection and HRS-3738 tablets, indicating progress in their drug development pipeline [1] Group 1: Clinical Trial Approval - Jiangsu Heng Rui Medicine Co., Ltd. and its subsidiaries have been granted the Clinical Trial Approval Notice for SHR-9539 injection and HRS-3738 tablets [1] - The approval is based on the review under the Drug Administration Law of the People's Republic of China, confirming that the drugs meet the registration requirements [1] - The specific study involves a Phase I/II trial of SHR-9539 in combination therapy for multiple myeloma [1]